Winfect-OZ Tablet contains a combination of Ofloxacin 200 mg and Ornidazole 500 mg, providing a broad-spectrum antimicrobial therapy effective against various bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication and transcription, leading to bacterial cell death. Ornidazole, a nitroimidazole derivative, exhibits potent activity against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing strand breakage. This synergistic combination is indicated for the treatment of mixed infections involving susceptible aerobic and anaerobic bacteria, including gastrointestinal infections, genitourinary tract infections, respiratory tract infections, skin and soft tissue infections, and certain protozoal diseases such as amoebiasis and giardiasis. Winfect-OZ should be administered as prescribed by a healthcare professional, with dosage adjusted according to the severity of infection and patient-specific factors such as renal function. Common side effects may include gastrointestinal disturbances, dizziness, and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and in those with hepatic or renal impairment. Complete the full course of therapy to prevent resistance development and ensure optimal clinical outcomes.